Testing Status of Kava kava extract M990058
CASRN: 9000-38-8
Related: KAWAIN (CAS: 1635-33-2)
Synonyms/Common Names
- Kava-Kava resin (8CI)
- Piper methisticum extract
Short-Term Toxicity
- 2 weeks (Gavage)
(C20007)
Completed
- (Peer Review Approval 01/26/2011A ) Citation: Yamashita H, Hoenerhoff MJ, Peddada SD, Sills RC, Pandiri AR. Chemical exacerbation of light-induced retinal degeneration in F344/n rats in National Toxicology Program rodent bioassays. Toxicol Pathol. 2016 Aug;44(6):892-903
- Rats: F344/N; Mice: B6C3F1/N
- Dose: R&M: 0, 0.125, 0.25, 0.5, 1.0, OR 2.0 G/KG; 5/SEX/SPECIES/DOSE.
- 13 weeks (Gavage)
(C20007)
Completed
- Citation: Yamashita H, Hoenerhoff MJ, Peddada SD, Sills RC, Pandiri AR. Chemical exacerbation of light-induced retinal degeneration in F344/n rats in National Toxicology Program rodent bioassays. Toxicol Pathol. 2016 Aug;44(6):892-903
- Rats: F344/N; Mice: B6C3F1/N
- Dose: R&M: 0, 0.125, 0.25, 0.5, 1.0, OR 2.0 G/KG; R: 20/SEX/DOSE; M: 10/SEX/DOSE.
Long-Term Carcinogenicity
- 2 years (Gavage)
(C20007)
Completed
- (Peer Review Approval 01/26/2011A ) Citation: Yamashita H, Hoenerhoff MJ, Peddada SD, Sills RC, Pandiri AR. Chemical exacerbation of light-induced retinal degeneration in F344/n rats in National Toxicology Program rodent bioassays. Toxicol Pathol. 2016 Aug;44(6):892-903
- TR-571 (NIH Number: 11-5913)
(Peer Review Approval 01/26/2011A )
Toxicology and Carcinogenesis Studies of Kava Kava Extract (CASRN 9000-38-8) in F344/N Rats and B6C3F1 Mice (Gavage Studies) - Rats: F344/N; Mice: B6C3F1/N
- Dose: R: 0, 0.1, 0.3, OR 1.0 G/KG; M: 0, 0.25, 0.5, OR 1.0 G/KG; 50/SEX/SPECIES/DOSE.
- Carcinogenesis Results
- Male Rats Equivocal Evidence
- Female Rats No Evidence
- Male Mice Clear Evidence
- Female Mice Clear Evidence
Special Studies
- Absorption Distribution Metabolism Excretion (Gavage; Intravenous)
(S0828)
Completed
- Citation: Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos. 2002 Nov;30(11):1153-7.Pubmed Abstract
- Male Rats [R]: F344/N
- Dose: (gavage) 100 mg/kg [R]. (intravenous) 7 mg/kg [R].
- Absorption Distribution Metabolism Excretion (Gavage; Intravenous; in-vitro)
(S0855)
Completed
- Citation: Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos. 2002 Nov;30(11):1153-7.Pubmed Abstract
- Citation: Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P, So J, Burka, LT. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract & kavalactones in vivo & in vitro. Drug Metab Dispos. 2005 Oct; 33(10): 1555-63. Epub 2005 Jul 20.Pubmed Abstract
- Male and Female Rats [R]: F344/N; Human (Cell Lines) [HU]
- Dose: (gavage) 0, 1, 10, 100 uM [R]. (intravenous) 0, 1, 10, 100 uM [R]. (in-vitro) 0, 1, 10, 100 uM [HU].
Genetic Toxicology
- Micronucleus
(A53705)
Completed
- Mice: B6C3F1
- Male Negative
- Female Negative
- 24 hours Micronucleus (in-vitro) Selected (G99058B)
- Human (Cell Lines)
- Salmonella
(A00186)
Completed
- Negative
- Salmonella
(A88186)
Completed
- Negative
- Salmonella (in-vitro) Selected (G99058)